Background: It is essentialfor a family physician to select people who would need immediate lifestylechanges to prevent a disease. There is evidence that fatty liver and omentin isrelated to cardiovascular diseases risks, however, there is still a gap ofknowledge regarding omentin as an early marker of increased risk of hepaticsteatosis and cardiovascular disease.
Aim: To find out if there is adifference between omentin levels in people with and without hepatic steatosis
Methods: A trans-sectional study in Riga, Latvia included 92 clinicallyhealthy individuals having body mass index (BMI) above 25 m2/kg andbelow 40 m2/kg and in age group 30-45 that visited primary carephysician. Individuals underwent CT scan for signs of hepatic steatosis andwere divided in two groups: individuals with and without any signs of fattyliver. All individuals were tested for omentin levels using enzyme-linked immunosorbent assay (ELISA) test. Independent samples t test was employed tocompare the means of the two groups.
Results: We observed that individuals withno signs of fatty liver had higher omentin levels (124,6±74,5 ng/ml; n=56) thanthose having signs of fatty liver (99,3±51,9 ng/ml; n=36). This difference (25,4±13,2ng/ml, 95% CI [0,085, 51,62] was not significant t(89,3)=1,92; p=0,058.
Conclusions: For individualsresiding in Riga, Latvia presence of omentin level alone cannot be consideredas an indicator of fatty liver and its related cardiovascular diseases risk.More research has to be done to find out more precise indicators.
|Number of pages||1|
|Publication status||Published - 2015|
|Event||20th WONCA Europe Conference 2015: Being Young Staying Young - Istanbul, Turkey|
Duration: 22 Oct 2015 → 25 Oct 2015
Conference number: 20
|Conference||20th WONCA Europe Conference 2015|
|Period||22/10/15 → 25/10/15|
- fatty liver
Field of Science*
- 3.2 Clinical medicine
- 3.4. Other publications in conference proceedings (including local)